254 related articles for article (PubMed ID: 9129064)
1. Evaluation of pharmacokinetics, safety, tolerance, and activity of combination of zalcitabine and zidovudine in stable, zidovudine-treated pediatric patients with human immunodeficiency virus infection. AIDS Clinical Trials Group Protocol 190 Team.
Bakshi SS; Britto P; Capparelli E; Mofenson L; Fowler MG; Rasheed S; Schoenfeld D; Zimmer B; Frank Y; Yogev R; Jimenez E; Salgo M; Boone G; Pahwa SG
J Infect Dis; 1997 May; 175(5):1039-50. PubMed ID: 9129064
[TBL] [Abstract][Full Text] [Related]
2. Zidovudine monotherapy versus zidovudine plus zalcitabine combination therapy in HIV-positive persons with CD4 cell counts 300-500 cells/mm3: a double-blind controlled trial. The M50003 Study Group Coordinating and Writing Committee.
Moyle GJ; Bouza E; Antunes F; Smith D; Harris R; Warburg M; Walker M
Antivir Ther; 1997 Dec; 2(4):229-36. PubMed ID: 11327442
[TBL] [Abstract][Full Text] [Related]
3. Combination and monotherapy with zidovudine and zalcitabine in patients with advanced HIV disease. The NIAID AIDS Clinical Trials Group.
Fischl MA; Stanley K; Collier AC; Arduino JM; Stein DS; Feinberg JE; Allan JD; Goldsmith JC; Powderly WG
Ann Intern Med; 1995 Jan; 122(1):24-32. PubMed ID: 7985892
[TBL] [Abstract][Full Text] [Related]
4. Phase II, randomized, open-label, community-based trial to compare the safety and activity of combination therapy with recombinant interferon-alpha2b and zidovudine versus zidovudine alone in patients with asymptomatic to mildly symptomatic HIV infection. HIV Protocol C91-253 Study Team.
Krown SE; Aeppli D; Balfour HH
J Acquir Immune Defic Syndr Hum Retrovirol; 1999 Mar; 20(3):245-54. PubMed ID: 10077172
[TBL] [Abstract][Full Text] [Related]
5. Zidovudine alone or in combination with didanosine or zalcitabine in HIV-infected patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimeter. Investigators for the Terry Beirn Community Programs for Clinical Research on AIDS.
Saravolatz LD; Winslow DL; Collins G; Hodges JS; Pettinelli C; Stein DS; Markowitz N; Reves R; Loveless MO; Crane L; Thompson M; Abrams D
N Engl J Med; 1996 Oct; 335(15):1099-106. PubMed ID: 8813040
[TBL] [Abstract][Full Text] [Related]
6. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group.
Collier AC; Coombs RW; Schoenfeld DA; Bassett RL; Timpone J; Baruch A; Jones M; Facey K; Whitacre C; McAuliffe VJ; Friedman HM; Merigan TC; Reichman RC; Hooper C; Corey L
N Engl J Med; 1996 Apr; 334(16):1011-7. PubMed ID: 8598838
[TBL] [Abstract][Full Text] [Related]
7. Zalcitabine compared with zidovudine in patients with advanced HIV-1 infection who received previous zidovudine therapy.
Fischl MA; Olson RM; Follansbee SE; Lalezari JP; Henry DH; Frame PT; Remick SC; Salgo MP; Lin AH; Nauss-Karol C; Lieberman J; Soo W
Ann Intern Med; 1993 May; 118(10):762-9. PubMed ID: 8097082
[TBL] [Abstract][Full Text] [Related]
8. Combination therapy with zidovudine and dideoxycytidine in patients with advanced human immunodeficiency virus infection. A phase I/II study.
Meng TC; Fischl MA; Boota AM; Spector SA; Bennett D; Bassiakos Y; Lai SH; Wright B; Richman DD
Ann Intern Med; 1992 Jan; 116(1):13-20. PubMed ID: 1345755
[TBL] [Abstract][Full Text] [Related]
9. A randomized comparative trial of stavudine (d4T) versus zidovudine (ZDV, AZT) in children with human immunodeficiency virus infection. AIDS Clinical Trials Group 240 Team.
Kline MW; Van Dyke RB; Lindsey JC; Gwynne M; Culnane M; McKinney RE; Nichols S; Mitchell WG; Yogev R; Hutcheon N
Pediatrics; 1998 Feb; 101(2):214-20. PubMed ID: 9445494
[TBL] [Abstract][Full Text] [Related]
10. A comparative trial of didanosine or zalcitabine after treatment with zidovudine in patients with human immunodeficiency virus infection. The Terry Beirn Community Programs for Clinical Research on AIDS.
Abrams DI; Goldman AI; Launer C; Korvick JA; Neaton JD; Crane LR; Grodesky M; Wakefield S; Muth K; Kornegay S
N Engl J Med; 1994 Mar; 330(10):657-62. PubMed ID: 7906384
[TBL] [Abstract][Full Text] [Related]
11. Virologic and immunologic benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared with zidovudine monotherapy. Wellcome Resistance Study Collaborative Group.
Schooley RT; Ramirez-Ronda C; Lange JM; Cooper DA; Lavelle J; Lefkowitz L; Moore M; Larder BA; St Clair M; Mulder JW; McKinnis R; Pennington KN; Harrigan PR; Kinghorn I; Steel H; Rooney JF
J Infect Dis; 1996 Jun; 173(6):1354-66. PubMed ID: 8648207
[TBL] [Abstract][Full Text] [Related]
12. Zalcitabine. An update of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of HIV infection.
Adkins JC; Peters DH; Faulds D
Drugs; 1997 Jun; 53(6):1054-80. PubMed ID: 9179531
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group.
Katlama C; Ingrand D; Loveday C; Clumeck N; Mallolas J; Staszewski S; Johnson M; Hill AM; Pearce G; McDade H
JAMA; 1996 Jul; 276(2):118-25. PubMed ID: 8656503
[TBL] [Abstract][Full Text] [Related]
14. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team.
Hammer SM; Katzenstein DA; Hughes MD; Gundacker H; Schooley RT; Haubrich RH; Henry WK; Lederman MM; Phair JP; Niu M; Hirsch MS; Merigan TC
N Engl J Med; 1996 Oct; 335(15):1081-90. PubMed ID: 8813038
[TBL] [Abstract][Full Text] [Related]
15. Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial.
Lancet; 1997 May; 349(9063):1413-21. PubMed ID: 9164314
[TBL] [Abstract][Full Text] [Related]
16. Exposure-response relationships for saquinavir, zidovudine, and zalcitabine in combination therapy.
Vanhove GF; Gries JM; Verotta D; Sheiner LB; Coombs R; Collier AC; Blaschke TF
Antimicrob Agents Chemother; 1997 Nov; 41(11):2433-8. PubMed ID: 9371346
[TBL] [Abstract][Full Text] [Related]
17. Data and safety monitoring in the Delta trial.
Armitage P
Control Clin Trials; 1999 Jun; 20(3):229-41. PubMed ID: 10357496
[TBL] [Abstract][Full Text] [Related]
18. Clinical efficacy of monotherapy with stavudine compared with zidovudine in HIV-infected, zidovudine-experienced patients. A randomized, double-blind, controlled trial. Bristol-Myers Squibb Stavudine/019 Study Group.
Spruance SL; Pavia AT; Mellors JW; Murphy R; Gathe J; Stool E; Jemsek JG; Dellamonica P; Cross A; Dunkle L
Ann Intern Med; 1997 Mar; 126(5):355-63. PubMed ID: 9054279
[TBL] [Abstract][Full Text] [Related]
19. A randomized double-blind trial of the addition of lamivudine or matching placebo to current nucleoside analogue reverse transcriptase inhibitor therapy in HIV-infected children: the PENTA-4 trial. Paediatric European Network for Treatment of AIDS.
AIDS; 1998 Oct; 12(14):F151-60. PubMed ID: 9792371
[TBL] [Abstract][Full Text] [Related]
20. Zidovudine, didanosine, and zalcitabine in the treatment of HIV infection: meta-analyses of the randomised evidence. HIV Trialists' Collaborative Group.
Lancet; 1999 Jun; 353(9169):2014-25. PubMed ID: 10376616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
